In LCLs from heterozygous carriers of a FA subtype N (FancN/PALB2)-mutation, which increases breast cancer risk six-fold [50], we previously found a relative increase of total NHEJ, but to a significantly lesser extent than SSA [25]. This evidence concerns the gene PALB2 and breast cancer.